Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer
Status:
Terminated
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to investigate whether the addition of the new anti-cancer
drug bevacizumab (Avastin) to the combination of the chemotherapeutic agents capecitabine
(Xeloda) and oxaliplatin (Eloxatin) reduces (slows down) the recurrence of metastatic disease
after a radical resection of liver metastases in patients with colorectal cancer.